Aurobindo Pharma Ltd. and Others See FDA Withdraw Approval of 86 Abbreviated New Drug Applications

Summary

The US Food and Drug Administration (FDA) is withdrawing approval of 86 abbreviated new drug applications (ANDAs) from multiple applicants, following written notifications from the applicants that the corresponding drug products are no longer commercially available.